Osteocalcin Antibody (N-term)
Purified Rabbit Polyclonal Antibody (Pab)
- 产品详情
- 实验流程
- 背景知识
Application ![]()
| WB, IHC-P, E |
---|---|
Primary Accession | P02818 |
Other Accession | NP_954642 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 10963 Da |
Antigen Region | 2-32 aa |
Gene ID | 632 |
---|---|
Other Names | Osteocalcin, Bone Gla protein, BGP, Gamma-carboxyglutamic acid-containing protein, BGLAP |
Target/Specificity | This Osteocalcin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 2-32 amino acids from the N-terminal region of human Osteocalcin. |
Dilution | WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration. |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | Osteocalcin Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | BGLAP |
---|---|
Function | Bone protein that constitutes 1-2% of the total bone protein, and which acts as a negative regulator of bone formation (PubMed:3019668, PubMed:6967872). Functions to limit bone formation without impairing bone resorption or mineralization (By similarity). It binds strongly to apatite and calcium (PubMed:6967872). |
Cellular Location | Secreted. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2% of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.
REFERENCES
Yamada, Y., et al., J. Clin. Endocrinol. Metab. 88(7):3372-3378 (2003). Gronthos, S., et al., J. Bone Miner. Res. 18(4):716-722 (2003). Yousfi, M., et al., Biochem. Biophys. Res. Commun. 297(3):641-644 (2002). Willis, D.M., et al., J. Biol. Chem. 277(40):37280-37291 (2002). Viereck, V., et al., J. Cell. Biochem. 86(2):348-356 (2002).

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.